Literature DB >> 35847473

Risk Factors, Screening, Diagnosis, and Treatment of Osteoporosis in HIV-Infected Adults in an HIV Primary Care Clinic.

Kevin Kwok1, Caitlin Olatunbosun2, Erin Ready3, Osric Sin4, Junine Toy5, Alena Spears6, Vickie Lau7, Greg Bondy8, Sarah Stone8.   

Abstract

Background: The population of people living with HIV is aging, and with aging come emergent comorbidities, including osteoporosis, for which screening and treatment are becoming increasingly important. Osteoporosis prevalence among those living with HIV is 3 times greater than among HIV-uninfected controls. Objective: To assess and describe osteoporosis risk factors, screening, diagnosis, and treatment for people 50 years of age or older living with HIV and receiving care at a multidisciplinary HIV primary care clinic.
Methods: A retrospective chart review of people 50 years of age or older living with HIV was conducted at the John Ruedy Clinic in Vancouver, British Columbia, between June 1, 2016, and June 1, 2019. Patients who had had fewer than 2 yearly follow-up appointments were excluded.
Results: A total of 146 patients were included in the analysis; most were male (n = 134, 92%), and the median age was 55 years. Patients had a median of 3 osteoporosis risk factors (in addition to age and HIV infection), and 145 patients had at least 1 risk factor. All screening for osteoporosis was conducted by dual-energy X-ray absorptiometry (DXA). Thirty-nine (27%) of the patients were screened with DXA, 92 (63%) were not screened, and 15 (10%) already had a diagnosis of osteoporosis. The DXA screening identified osteoporosis in an additional 10 patients and osteopenia in 22 patients. Treatments for patients with osteoporosis included bisphosphonates (n = 15, 60%) and vitamin D or calcium (or both), without any other medications (n = 4, 16%). In the overall study population, 32 (22%) of the patients were taking calcium and 46 (32%) were taking vitamin D. Conclusions: Many patients aged 50 years or older and receiving HIV care at the John Ruedy Clinic had or were at risk for osteoporosis. An opportunity exists to increase screening and treatment of these individuals. A multidisciplinary team may be crucial in achieving this goal. 2022 Canadian Society of Hospital Pharmacists. All content in the Canadian Journal of Hospital Pharmacy is copyrighted by the Canadian Society of Hospital Pharmacy. In submitting their manuscripts, the authors transfer, assign, and otherwise convey all copyright ownership to CSHP.

Entities:  

Keywords:  HIV; VIH; dépistage; facteurs de risque; osteoporosis; ostéoporose; risk factors; screening; traitement; treatment

Year:  2022        PMID: 35847473      PMCID: PMC9245408          DOI: 10.4212/cjhp.3144

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN: 0008-4123


  28 in total

1.  Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.

Authors:  David Rey; Michele Treger; Jean Sibilia; Michele Priester; Claudine Bernard-Henry; Christine Cheneau; Rose-Marie Javier
Journal:  Infect Dis (Lond)       Date:  2014-11-26

2.  Recommendations for evaluation and management of bone disease in HIV.

Authors:  Todd T Brown; Jennifer Hoy; Marco Borderi; Giovanni Guaraldi; Boris Renjifo; Fabio Vescini; Michael T Yin; William G Powderly
Journal:  Clin Infect Dis       Date:  2015-01-21       Impact factor: 9.079

3.  Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

Authors:  Judith A Aberg; Joel E Gallant; Khalil G Ghanem; Patricia Emmanuel; Barry S Zingman; Michael A Horberg
Journal:  Clin Infect Dis       Date:  2013-11-13       Impact factor: 9.079

4.  Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.

Authors:  Grace A McComsey; Michelle A Kendall; Pablo Tebas; Susan Swindells; Evelyn Hogg; Beverly Alston-Smith; Carol Suckow; Geetha Gopalakrishnan; Constance Benson; David A Wohl
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

5.  Evaluation of the fracture risk assessment tool for determining bone disease and the impact of secondary causes of osteoporosis in people living with HIV.

Authors:  Pilar Vizcarra; Juan Gallego; María J Vivancos; Walter A Sifuentes; María Llop; José L Casado
Journal:  HIV Res Clin Pract       Date:  2020-07-23

6.  Risk factors for osteoporotic fractures in elderly men.

Authors:  T V Nguyen; J A Eisman; P J Kelly; P N Sambrook
Journal:  Am J Epidemiol       Date:  1996-08-01       Impact factor: 4.897

7.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

8.  A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.

Authors:  Mario Gomez; Ulrich Seybold; Julia Roider; Georg Härter; Johannes R Bogner
Journal:  Infection       Date:  2018-09-29       Impact factor: 3.553

9.  Performance of fracture risk assessment tool in HIV-positive male individuals aged ≥45 years on suppressive antiretroviral therapy.

Authors:  Mao-Song Tsai; Jun-Yu Zhang; Hsin-Yun Sun; Wen-Chun Liu; Pei-Ying Wu; Chia-Jui Yang; Chien-Ching Hung
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396

10.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

Authors:  Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister
Journal:  Lancet Infect Dis       Date:  2015-11-02       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.